Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KEITH A BAGGERLY and ANIL K SOOD.
KEITH A BAGGERLY
Connection Strength
4.653
ANIL K SOOD
  1. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29; 474(7353):609-15.
    View in: PubMed
    Score: 0.391
  2. Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma. Cancers (Basel). 2022 Aug 30; 14(17).
    View in: PubMed
    Score: 0.212
  3. Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Mol Cancer Res. 2021 11; 19(11):1917-1928.
    View in: PubMed
    Score: 0.197
  4. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2021 04 08; 6(7).
    View in: PubMed
    Score: 0.192
  5. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.190
  6. Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer. Mol Cancer Ther. 2020 09; 19(9):1943-1954.
    View in: PubMed
    Score: 0.183
  7. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.180
  8. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. EBioMedicine. 2019 May; 43:127-137.
    View in: PubMed
    Score: 0.168
  9. Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. Mol Cancer Ther. 2019 02; 18(2):421-436.
    View in: PubMed
    Score: 0.163
  10. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018 11 01; 4(11):1519-1526.
    View in: PubMed
    Score: 0.163
  11. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018 07 26; 9(1):2923.
    View in: PubMed
    Score: 0.160
  12. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2018 Jun 07; 3(11).
    View in: PubMed
    Score: 0.158
  13. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget. 2018 May 18; 9(38):25115-25126.
    View in: PubMed
    Score: 0.157
  14. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.
    View in: PubMed
    Score: 0.150
  15. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017 Aug 17; 2(16).
    View in: PubMed
    Score: 0.149
  16. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017; 1(1):26.
    View in: PubMed
    Score: 0.149
  17. Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. Gynecol Oncol. 2017 07; 146(1):101-108.
    View in: PubMed
    Score: 0.147
  18. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04; 7:11169.
    View in: PubMed
    Score: 0.136
  19. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.
    View in: PubMed
    Score: 0.134
  20. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther. 2014 Jul; 15(7):919-29.
    View in: PubMed
    Score: 0.119
  21. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3280-8.
    View in: PubMed
    Score: 0.119
  22. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.119
  23. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.
    View in: PubMed
    Score: 0.118
  24. Autocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095.
    View in: PubMed
    Score: 0.118
  25. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
    View in: PubMed
    Score: 0.114
  26. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.108
  27. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
    View in: PubMed
    Score: 0.108
  28. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
    View in: PubMed
    Score: 0.099
  29. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.085
  30. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 04 09; 33(4):690-705.e9.
    View in: PubMed
    Score: 0.039
  31. A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression. Mol Syst Biol. 2015 Dec 11; 11(12):842.
    View in: PubMed
    Score: 0.033
  32. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351.
    View in: PubMed
    Score: 0.032
  33. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015; 14(14):2265-73.
    View in: PubMed
    Score: 0.032
  34. BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Mol Oncol. 2014 Dec; 8(8):1429-40.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.